Fundraising Fox
🦊/Companies
Sign in

AntriaBio

NASDAQ: RZLT

Louisville, US · Founded 2010 · Nevada corporation · 1 known investors

Find your way into AntriaBio

Rezolute develops ersodetug, an intravenously administered monoclonal antibody targeting the insulin receptor to treat hypoglycemia caused by hyperinsulinism, with late-stage clinical programs in congenital hyperinsulinism and tumor-related hyperinsulinism.

Biotech

Founders & leadership

SM
Sankaram MantripragadaExecutive
NC
Nevan Charles ElamExecutive
ML
Morgan Lynn FieldsExecutive
BR
Brian RobertsChief Medical Officer
DE
Daron EvansChief Financial Officer
SK
Sunil KarnawatChief Commercial Officer

Board

HH
Hoyoung HuhBoard director
BS
Barry ShermanBoard director
SR
Steve R. HoweBoard director

Investors · 1

Bay City CapitalSan Rafael · $5M – $10M

Reported raises · per SEC filings

Form D private placements

$85M disclosed across 11 rounds · 2013–2020

▶$41MraisedOct 2020 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith VendolaExecutive Officer
  • Young-Jin KimDirector
  • Jung-Hee LimDirector
  • Philippe FauchetDirector
  • Sankaram MantripragadaExecutive Officer
  • Nevan Charles ElamExecutive Officer, Director
  • Gil LabrucherieDirector
Offering amount
$57M
Amount sold
$41M
Sales commissions
$2.5M
Placement agents
Griffin Securities, Inc., JMP Securities LLC, Canaccord Genuity LLC
First sale
Oct 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.8MraisedApr 2018 · 34 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David F. WelchDirector
  • Hoyoung HuhExecutive Officer, Director
  • Gil LabrucherieDirector
  • Sankaram MantripragadaExecutive Officer
  • Morgan Lynn FieldsExecutive Officer
  • Tae Hoon KimDirector
  • Brian RobertsExecutive Officer
  • Noopur Batsha LiffickExecutive Officer
  • Michael R. DeperroExecutive Officer
  • Samir R. PatelDirector
  • Nevan Charles ElamExecutive Officer, Director
Offering amount
$6M
Amount sold
$4.8M
Sales commissions
$202.3K
Placement agents
Brookline Capital Markets, a division of CIM Securities, LLC
First sale
Jan 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.4MraisedFeb 2018 · 190 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tae Hoon KimDirector
  • Gil LabrucherieDirector
  • Nevan Charles ElamExecutive Officer, Director
  • Morgan Lynn FieldsExecutive Officer
  • Hoyoung HuhExecutive Officer, Director
  • David F. WelchDirector
  • Michael R. DeperroExecutive Officer
  • Samir R. PatelDirector
  • Noopur Batsha LiffickExecutive Officer
  • Sankaram MantripragadaExecutive Officer
  • Brian RobertsExecutive Officer
Offering amount
$25.4M
Amount sold
$3.4M
First sale
Jan 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$137.9KraisedJan 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tae Hoon KimDirector
  • Sankaram MantripragadaExecutive Officer
  • David F. WelchDirector
  • Brian RobertsExecutive Officer
  • Michael R. DeperroExecutive Officer
  • Noopur Batsha LiffickExecutive Officer
  • Samir R. PatelDirector
  • Hoyoung HuhExecutive Officer, Director
  • Gil LabrucherieDirector
  • Nevan Charles ElamExecutive Officer, Director
  • Morgan Lynn FieldsExecutive Officer
Offering amount
$10.1M
Amount sold
$137.9K
First sale
Dec 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.7MraisedMay 2017 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nevan Charles ElamExecutive Officer, Director
  • Tae Hoon KimDirector
  • Brian RobertsExecutive Officer
  • Sankaram MantripragadaExecutive Officer
  • David F. WelchDirector
  • Morgan Lynn FieldsExecutive Officer
  • Barry ShermanDirector
  • Michael R. DeperroExecutive Officer
  • Samir R. PatelDirector
  • Noopur Batsha LiffickExecutive Officer
  • Hoyoung HuhExecutive Officer, Director
Offering amount
$15M
Amount sold
$6.7M
First sale
Mar 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.4MraisedJul 2016 · 60 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Hoyoung HuhExecutive Officer, Director
  • Morgan Lynn FieldsExecutive Officer
  • David WelchDirector
  • Sankaram MantripragadaExecutive Officer
  • Barry ShermanDirector
  • Nevan Charles ElamExecutive Officer, Director
Offering amount
$53.3M
Amount sold
$5.4M
Sales commissions
$2M
Placement agents
CIM Securities, LLC, Paulson Investment Company, Inc.
First sale
Jun 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.3MraisedMar 2016 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Barry ShermanDirector
  • Morgan Lynn FieldsExecutive Officer
  • Nevan Charles ElamExecutive Officer, Director
  • Hoyoung HuhExecutive Officer, Director
  • Sankaram MantripragadaExecutive Officer
  • David WelchDirector
Offering amount
$16.7M
Amount sold
$4.3M
Sales commissions
$737.5K
Placement agents
CIM Securities, LLC, Brookline Group, LLC
First sale
Dec 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedApr 2015 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Barry ShermanDirector
  • Hoyoung HuhDirector, Executive Officer
  • Morgan Lynn FieldsExecutive Officer
  • Nevan Charles ElamExecutive Officer, Director
  • Sankaram MantripragadaExecutive Officer
Offering amount
$4.7M
Amount sold
$2M
Sales commissions
$98.4K
Placement agents
Paulson Investment Company, Inc.
First sale
Mar 2015
Incorporated
Corporation, Delaware, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

AntriaBio raises $13m for injectable, once-weekly insulin - Drug Delivery Businessdrugdeliverybusiness.com · Jul 2017AntriaBio, Inc. announced that it expects to receive $15 million in funding | MarketScreenermarketscreener.com · Mar 2017AntriaBio snaps up $12M in private placement deal | Fierce Pharmafiercepharma.com · Jul 2016AntriaBio Announces $12 Million Private Placementfinance.yahoo.com · Jun 2016AntriaBio raises $7 million to work on insulin – BizWestbizwest.com · Jan 2015

Frequently asked questions

What does AntriaBio do?
Rezolute develops ersodetug, an intravenously administered monoclonal antibody targeting the insulin receptor to treat hypoglycemia caused by hyperinsulinism, with late-stage clinical programs in congenital hyperinsulinism and tumor-related hyperinsulinism.
Who are AntriaBio's investors?
AntriaBio's investors include Bay City Capital.
How much funding has AntriaBio raised?
AntriaBio has disclosed $85M raised across 11 rounds.
Where is AntriaBio headquartered?
AntriaBio is headquartered in Louisville, US.